Treatment Efficacy with a Novel Hyaluronic Acid-Based Hydrogel for Osteoarthritis of the Knee
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Vos, T.; Flaxman, A.D.; Naghavi, M.; Lozano, R.; Michaud, C.; Ezzati, M.; Shibuya, K.; Salomon, J.A.; Abdalla, S.; Aboyans, V.; et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: A systematic analysis for the global burden of disease study 2010. Lancet 2012, 380, 2163–2196. [Google Scholar] [CrossRef]
- Altman, R.D.; Akermark, C.; Beaulieu, A.D.; Schnitzer, T. Efficacy and safety of a single intraarticular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. Osteoarthr. Cartil. 2004, 12, 642–649. [Google Scholar] [CrossRef]
- Altman, R.; Lim, S.; Steen, R.G.; Dasa, V. Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: Evidence from a large U.S. health claims database. PLoS ONE 2015, 10, e0145776. [Google Scholar] [CrossRef]
- McAlindon, T.E.; Bannuru, R.R.; Sullivan, M.C.; Arden, N.K.; Berenbaum, F.; Bierma-Zeinstra, S.M.; Hawker, G.A.; Henrotin, Y.; Hunter, D.J.; Kawaguchi, H. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr. Cartil. 2014, 22, 363–388. [Google Scholar] [CrossRef] [PubMed]
- Jones, I.A.; Togashi, R.; Wilson, M.L.; Heckmann, N.; Vangsness, C.T. Intra-articular treatment options for knee osteoarthritis. Nat. Rev. Rheumatol. 2019, 15, 77–90. [Google Scholar] [CrossRef] [PubMed]
- da Costa, B.R.; Reichenbach, S.; Keller, N.; Nartey, L.; Wandel, S.; Jüni, P.; Trelle, S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: A network meta-analysis. Lancet 2016, 387, 2093–2105. [Google Scholar] [CrossRef]
- Bjorkman, D. Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am. J. Med. 1998, 105, 17S–21S. [Google Scholar] [CrossRef]
- Biskupiak, J.E.; Brixner, D.I.; Howard, K.; Oderda, G.M. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J. Pain Palliat. Care Pharmacother. 2006, 20, 7–14. [Google Scholar] [CrossRef] [PubMed]
- McCarthy, D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: Definitions and epidemiology. Am. J. Med. 1998, 105, 3S–9S. [Google Scholar] [CrossRef]
- Massó González, E.L.; Patrignani, P.; Tacconelli, S.; García Rodríguez, L.A. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010, 62, 1592–1601. [Google Scholar] [CrossRef]
- Ofman, J.J.; MacLean, C.H.; Straus, W.L.; Morton, S.C.; Berger, M.L.; Roth, E.A.; Shekelle, P. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J. Rheumatol. 2002, 29, 804–812. [Google Scholar] [PubMed]
- O’Neil, C.K.; Hanlon, J.T.; Marcum, Z.A. Adverse effects of analgesics commonly used by older adults with osteoarthritis: Focus on non-opioid and opioid analgesics. Am. J. Geriatr. Pharmacother. 2012, 10, 331–342. [Google Scholar] [CrossRef]
- Weick, J.W.; Bawa, H.S.; Dirschl, D.R. Hyaluronic acid injections for treatment of advanced osteoarthritis of the knee: Utilization and cost in a national population sample. J. Bone Jt. Surg. 2016, 98, 1429–1435. [Google Scholar] [CrossRef]
- Kirwan, J. Is there a place for intra-articular hyaluronate in osteoarthritis of the knee? Knee 2001, 8, 93–101. [Google Scholar] [CrossRef]
- Leopold, S.S.; Redd, B.B.; Warme, W.J.; Wehrle, P.A.; Pettis, P.D.; Shott, S. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. A prospective, randomized trial. J. Bone Jt. Surg. 2003, 85, 1197–1203. [Google Scholar] [CrossRef] [PubMed]
- Bannuru, R.R.; Schmid, C.H.; Kent, D.M.; Vaysbrot, E.E.; Wong, J.B.; McAlindon, T.E. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: A systematic review and network meta-analysis. Ann. Intern. Med. 2015, 162, 46–54. [Google Scholar] [CrossRef] [PubMed]
- Ricci, M.; Micheloni, G.M.; Berti, M.; Perusi, F.; Sambugaro, E.; Vecchini, E.; Magnan, B. Clinical comparison of oral administration and viscosupplementation of hyaluronic acid (HA) in early knee osteoarthritis. Musculoskelet. Surg. 2016, 101, 45–49. [Google Scholar] [CrossRef] [PubMed]
- Balazs, E.A. The physical properties of synovial fluid and the special role of hyaluronic acid. In Disorders of the Knee; Helfet, A., Ed.; T.B. Lippincott Company: Philadelphia, PA, USA, 1974; pp. 63–75. [Google Scholar]
- Gupta, C.R.; Lall, R.; Srivastava, A.; Sinha, A. Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory. Front. Vet. Sci. 2019, 6, 192. [Google Scholar] [CrossRef] [PubMed]
- Altman, R.D.; Manjoo, A.; Fierlinger, A.; Niazi, F.; Nicholls, M. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: A systematic review. BMC Musculoskelet. Disord. 2015, 16, 321. [Google Scholar] [CrossRef]
- Lin, W.; Klein, J. Recent progress in cartilage lubrication. Adv. Mater. 2021, 2005513. [Google Scholar] [CrossRef]
- Maharjan, A.S.; Pilling, D.; Gomer, R.H. High and low molecular weight hyaluronic acid differentially regulate human fibrocyte differentiation. PLoS ONE 2011, 6, e26078. [Google Scholar] [CrossRef]
- Ariyoshi, W.; Takahashi, T.; Kanno, T.; Ichimiya, H.; Takano, H.; Koseki, T.; Nishihara, T. Mechanisms involved in enhancement of osteoclast formation and function by low molecular weight hyaluronic acid. J. Biol. Chem. 2005, 280, 18967–18972. [Google Scholar] [CrossRef] [PubMed]
- Galesso, D. An innovative chemistry for intra-articular hyaluronic acid: The MO.RE.® technology, evolution of I.A.H.A therapy. Osteoartrosi 2013, 12, 3–7. [Google Scholar]
- Smith, M.M.; Russell, A.K.; Schiavinato, A.; Little, C.B. A hexadecylamide derivative of hyaluronan (HYMOVIS®) has superior beneficial effects on human osteoarthritic chondrocytes and synoviocytes than unmodified hyaluronan. J. Inflamm. 2013, 10, 26. [Google Scholar] [CrossRef] [PubMed]
- Shimizu, C.; Kubo, T.; Hirasawa, Y.; Coutts, R.D.; Amiel, D. Histomorphometric and biochemical effect of various hyaluronans on early osteoarthritis. J. Rheumatol. 1998, 25, 1813–1819. [Google Scholar]
- Scott, J.; Huskisson, E.C. Vertical or horizontal visual analogue scales. Ann. Rheum. Dis. 1979, 38, 560. [Google Scholar] [CrossRef]
- Jensen, M.P.; Karoly, P.; Braver, S. The measurement of clinical pain intensity: A comparison of six methods. Pain 1986, 27, 117–126. [Google Scholar] [CrossRef]
- Burckhardt, C.S.; Jones, K.D. Adult measures of pain: The McGill Pain Questionnaire (MPQ), Rheumatoid Arthritis Pain Scale (RAPS), Short-Form McGill Pain Questionnaire (SF-MPQ), Verbal Descriptive Scale (VDS), Visual Analog Scale (VAS), and West Haven-Yale Multidisciplinary Pain Inventory (WHYMPI). Arthritis Rheum. Arthritis Care Res. 2003, 49, S96–S104. [Google Scholar]
- Newberry, S.J.; Fitzgerald, J.D.; Maglione, M.A.; O’Hanlon, C.E.; Booth, M.; Motala, A.; Timmer, M.; Shanman, R.; Shekelle, P.G. Systematic Review for Effectiveness of Hyaluronic Acid in the Treatment of Severe Degenerative Joint Disease (DJD) of the Knee; Agency for Healthcare Research and Quality: Rockville, MD, USA, 2015.
- Altman, R.D.; Moskowitz, R.; Hyalgan Study Group. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: A randomized clinical trial. J. Rheumatol. 1998, 25, 2203–2212. [Google Scholar]
- Brandt, K.D.; Block, J.A.; Michalski, J.P.; Moreland, L.W.; Caldwell, J.R.; Lavin, P.T.; ORTHOVISC Study Group. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. Clin. Orthop. Relat. Res. 2001, 385, 130–143. [Google Scholar] [CrossRef]
- Karlsson, J.; Sjögren, L.S.; Lohmander, L.S. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology 2002, 41, 1240–1248. [Google Scholar] [CrossRef] [PubMed]
- Petrella, R.J.; DiSilvestro, M.D.; Hildebrand, C. Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled clinical trial. Arch. Intern. Med. 2002, 162, 292–298. [Google Scholar] [CrossRef]
- Kahan, A.; Lleu, P.L.; Salin, L. Prospective randomized study comparing the medicoeconomic benefits of Hylan GF-20 vs. conventional treatment in knee osteoarthritis. Jt. Bone Spine 2003, 70, 276–281. [Google Scholar] [CrossRef]
- Blanco, F.J.; Fernández, J.L.; Pinto, J.A.; Fernández, J.C.; Ramallal, M.; Freire, A.; Galdo, F. Intra-articular hyaluronan treatment of patients with knee osteoarthritis waiting for replacement surgery. Open Arthritis J. 2008, 1, 1–7. [Google Scholar] [CrossRef][Green Version]
- Raman, R.; Dutta, A.; Day, N.; Sharma, H.K.; Shaw, C.J.; Johnson, G.V. Efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee—A prospective randomized clinical trial. Knee 2008, 15, 318–324. [Google Scholar] [CrossRef]
- Huang, T.L.; Chang, C.C.; Lee, C.H.; Chen, S.C.; Lai, C.H.; Tsai, C.L. Intra-articular injections of sodium hyaluronate (Hyalgan(R)) in osteoarthritis of the knee. A randomized, controlled, double-blind, multicenter trial in the Asian population. BMC Musculoskelet. Disord. 2011, 12, 221. [Google Scholar] [CrossRef] [PubMed]
- Pavelka, K.; Uebelhart, D. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial(®)) vs hylan G-F20 (Synvisc(®)) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study. Osteoarthr. Cartil. 2011, 19, 1294–1300. [Google Scholar] [CrossRef][Green Version]
- Berenbaum, F.; Grifka, J.; Cazzaniga, S.; D’Amato, M.; Giacovelli, G.; Chevalier, X.; Rannou, F.; Rovati, L.C.; Maheu, E. A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Ann. Rheum. Dis. 2012, 71, 1454–1460. [Google Scholar] [CrossRef] [PubMed]
- DeCaria, J.E.; Montero-Odasso, M.; Wolfe, D.; Chesworth, B.M.; Petrella, R.J. The effect of intra-articular hyaluronic acid treatment on gait velocity in older knee osteoarthritis patients: A randomized, controlled study. Arch. Gerontol. Geriatr. 2012, 55, 310–315. [Google Scholar] [CrossRef] [PubMed]
- Khanasuk, Y.; Dechmaneenin, T.; Tanavalee, A. Prospective randomized trial comparing the efficacy of single 6-ml injection of hylan G-F 20 and hyaluronic acid for primary knee arthritis: A preliminary study. J. Med. Assoc. Thai. 2012, 95, 92–97. [Google Scholar]
- Benazzo, F.; Perticarini, L.; Padolino, A.; Castelli, A.; Gifuni, P.; Lovato, M.; Manzini, C.; Giordan, N. A multi-centre, open label, long term follow-up study to evaluate the benefits of a new viscoelastic hydrogel (Hymovis) in the treatment of knee osteoarthritis. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 959–968. [Google Scholar]
- Skwara, A.; Peterlein, C.D.; Tibesku, C.O.; Rosenbaum, D.; Fuchs-Winkelmann, S. Changes of gait patterns and muscle activity after intraarticular treatment of patients with osteoarthritis of the knee: A prospective, randomised, doubleblind study. Knee 2009, 16, 466–472. [Google Scholar] [CrossRef]
- Bannuru, R.R.; Natov, N.S.; Obadan, I.E.; Price, L.L.; Schmid, C.H.; McAlindon, T.E. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: A systematic review and meta-analysis. Arthritis Rheum. 2009, 61, 1704–1711. [Google Scholar] [CrossRef]
- Wang, F.; He, X. Intra-articular hyaluronic acid and corticosteroids in the treatment of knee osteoarthritis: A meta-analysis. Exp. Ther. Med. 2015, 9, 493–500. [Google Scholar]
- Leighton, R.; Akermark, C.; Therrien, R.; Richardson, J.B.; Andersson, M.; Todman, M.G.; Arden, N.K.; DUROLANE Study Group. NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: A prospective, multi-centre, randomized, non-inferiority trial. Osteoarthr. Cartil. 2014, 22, 17–25. [Google Scholar] [CrossRef]
- Tubach, F.; Ravaud, P.; Baron, G.; Falissard, B.; Logeart, I.; Bellamy, N.; Bombardier, C.; Felson, D.; Hochberg, M.; Van Der Heijde, D.; et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: The minimal clinically important improvement. Ann. Rheum. Dis. 2005, 64, 29–33. [Google Scholar] [CrossRef]
- Montañez-Heredia, E.; Irizar, S.; Huertas, P.J.; Otero, E.; Del Valle, M.; Prat, I.; Díaz-Gallardo, M.S.; Perán, M.; Marchal, J.A.; Hernandez-Lamas, M.D.C. Intra-Articular injections of platelet-rich plasma versus hyaluronic acid in the treatment of osteoarthritic knee pain: A randomized clinical trial in the context of the Spanish National Health Care System. Int. J. Mol. Sci. 2016, 17, 1064. [Google Scholar] [CrossRef]
- Askari, A.; Gholami, T.; NaghiZadeh, M.M.; Farjam, M.; Kouhpayeh, S.A.; Shahabfard, Z. Hyaluronic acid compared with corticosteroid injections for the treatment of osteoarthritis of the knee: A randomized control trail. SpringerPlus 2016, 5, 442. [Google Scholar] [CrossRef] [PubMed]
- Ray, T.R. Using viscosupplementation to treat knee osteoarthritis. Phys. Sportsmed. 2013, 41, 16–24. [Google Scholar] [CrossRef] [PubMed]
- Gaendam, A.; Ekhtiari, S.; Bozzo, A.; Phillips, M.; Bhandari, M. Intra-articular saline injection as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: A systematic review and network meta-analysis of randomised controlled trials. Br. J. Sports Med. 2021, 55, 256–261. [Google Scholar] [CrossRef]
- Han, S.B.; Seo, I.W.; Shin, Y.S. Intra-articular injections of hyaluronic acid or steroid associated with better outcomes than platelet-rich plasma, adipose mesenchymal stromal cell, or placebo in knee osteoarthritis: A network meta-analysis. Arthrosc. J. Arthrosc. Relat. Surg. 2021, 37, 292–306. [Google Scholar] [CrossRef] [PubMed]
- Vannabouathong, C.; Bhandari, M.; Bedi, A.; Khanna, V.; Yung, P.; Shetty, V.; Khan, M. Nonoperative treatments for knee osteoarthritis: An evaluation of treatment characteristics and the intra-articular placebo effect. JBJS Rev. 2018, 6, e5. [Google Scholar] [CrossRef] [PubMed]
- Testa, G.; Giardina, S.M.C.; Culmone, A.; Vescio, A.; Turchetta, M.; Pavone, S.C.V. Intra-articular injections in knee osteoarthritis: A review of literature. J. Funct. Morphol. Kinesiol. 2021, 6, 15. [Google Scholar] [CrossRef] [PubMed]
- Kersten, P.; White, P.J.; Tennant, A. The visual analogue WOMAC 3.0 scale-internal validity and responsiveness of the VAS version. BMC Musculoskelet. Disord. 2010, 11, 80. [Google Scholar] [CrossRef] [PubMed]
WOMAC Score per Subscale | p Value Comparison from Baseline | ||
---|---|---|---|
Mean | SD | ||
Pain before (baseline) | 10 | 3 | - |
Pain after 2 months | 9 | 2 | n.s. * |
Pain after 6 months | 8 | 1 | 0.0004 |
Stiffness before (baseline) | 3 | 1 | - |
Stiffness after 2 months | 3 | 1 | n.s. |
Stiffness after 6 months | 3 | 1 | n.s. |
Physical function before (baseline) | 30 | 8 | - |
Physical function after 2 months | 29 | 7 | n.s. |
Physical function after 6 months | 25 | 5 | 0.0025 |
Author & Year | Study Population | Treatment | Outcomes |
---|---|---|---|
Altman et al., 1998 [31] | 495 |
Group 1 (n = 115): placebo Group 2 (n = 105): Hyalgan 20 mg/2 mL (500–700 kDa) Group 3 (n = 113): NSAID | WOMAC physical function: Hyalgan improvement compared to placebo—p = 0.047 |
Brandt et al., 2001 [32] | 226 |
Group 1 (n = 112): placebo Group 2 (n = 114): Orthovisc 2 mL, 15 mg/mL (1000–2900 kDa—high molecular weight) |
WOMAC function Group 1: mean change from baseline: −9.8 Group 2: mean change from baseline: −14.7 p = 0.02 |
Karlsson et al., 2002 [33] | 246 |
Group 1 (n = 66): placebo Group 2 (n = 92): Artzal (2.5 mL 1% hyaluronan; 1000 kDa) Group 3 (n = 88): Synvisc (2 mL 0.8%; 7000 kDa) |
WOMAC physical function Group 1: mean change from baseline: −11.1 Group 2: mean change from baseline: −7.3 Group 3: mean change from baseline: −11.7 Group 3 vs. 2: standard mean difference −0.297 |
Petrella et al., 2002 [34] | 120 |
Group 1 (n = 28): placebo Group 2 (n = 25): Suplasyn (molecular weight not reported) Group 3 (n = 29): Suplasyn + NSAID Group 4 (n = 26): NSAID |
WOMAC Disability Group 1: mean change from baseline: −0.99 Group 2: mean change from baseline: −1.65 Group 3: mean change from baseline: −1.17 Group 4: mean change from baseline: −1.56 Standard mean difference: −0.234 |
Kahan et al., 2003 [35] | 506 |
Group 1 (n = 253): conventional treatment Group 2 (n = 253): Synvisc (molecular weight not reported) |
WOMAC function Group 1: mean change from baseline: −7 Group 2: mean change from baseline: −18.4 Standard mean difference: −0.567 |
Blanco et al., 2008 [36] | 42 |
Group 1 (n = 20): placebo Group 2 (n = 22): Adant (900 kDa) |
WOMAC physical function Group 1: mean change from baseline: −4.4 Group 2: mean change from baseline: −24.7 Standard mean difference: −1.080 |
Raman et al., 2008 [37] | 392 |
Group 1 (n = 199): Synvisc (Hylan GF 20 – 6000 kDa) Group 2 (n = 193): Hyalgan (500–730 kDa) |
WOMAC physical activity Group 1: mean change from baseline: −21.8 Group 2: mean change from baseline: −6.8 Standard mean difference: −0.882 |
Huang et al., 2011 [38] | 200 |
Group 1 (n = 100): Placebo Group 2 (n = 100): Hyalgan (20 mg/2 mL) |
WOMAC function Group 1: mean change from baseline: −18.2 Group 2: mean change from baseline −25.16 Standard mean difference: −0.415 |
Pavelka et al., 2011 [39] | 381 |
Group 1 (n = 192): Synovial (800−1200 kDa) Group 2 (n = 188): Synvisc (6000 kDa) |
WOMAC function Group 1: mean change from baseline 3.9 Group 2: mean change from baseline 3.4 Standard mean difference: −0.009 |
Berenbaum et al., 2012 [40] | 426 |
Group 1 (n = 209): Hyalgan (500−730 kDa) Group 2 (n = 217): GO-ON (2.5 mL, 10 mg/mL; 800–1500 kDa) |
WOMAC function Group 1: mean change from baseline: −15.4 Group 2: mean change from baseline: −22.2 Standard mean difference: −0.326 |
DeCaria et al., 2012 [41] | 30 |
Group 1 (n = 15): Placebo/acetaminophen Group 2 (n = 15): Hyaluronic acid (2 mL, 20mg/mL; 730 kDa) |
WOMAC function Group 1: mean change from baseline: −3.53 Group 2: mean change from baseline: −9.07 Standard mean difference: −0.586 |
Khanasuk et al., 2012 [42] | 32 |
Group 1 (n = 15): Synvisc (Hylan GF-20; single 6ml injection; high molecular weight) Group 2 (n = 15): Hyalgan (single injection; low molecular weight) |
WOMAC function Group 1: mean change from baseline: −20 Group 2: mean change from baseline: −22 Standard mean difference: 0.053 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Russu, O.M.; Pop, T.S.; Feier, A.M.; Trâmbițaș, C.; Incze-Bartha, Z.; Borodi, P.G.; Gergely, I.; Zuh, S.-G. Treatment Efficacy with a Novel Hyaluronic Acid-Based Hydrogel for Osteoarthritis of the Knee. J. Pers. Med. 2021, 11, 303. https://doi.org/10.3390/jpm11040303
Russu OM, Pop TS, Feier AM, Trâmbițaș C, Incze-Bartha Z, Borodi PG, Gergely I, Zuh S-G. Treatment Efficacy with a Novel Hyaluronic Acid-Based Hydrogel for Osteoarthritis of the Knee. Journal of Personalized Medicine. 2021; 11(4):303. https://doi.org/10.3390/jpm11040303
Chicago/Turabian StyleRussu, Octav Marius, Tudor Sorin Pop, Andrei Marian Feier, Cristian Trâmbițaș, Zsuzsanna Incze-Bartha, Paul Gabriel Borodi, István Gergely, and Sándor-György Zuh. 2021. "Treatment Efficacy with a Novel Hyaluronic Acid-Based Hydrogel for Osteoarthritis of the Knee" Journal of Personalized Medicine 11, no. 4: 303. https://doi.org/10.3390/jpm11040303
APA StyleRussu, O. M., Pop, T. S., Feier, A. M., Trâmbițaș, C., Incze-Bartha, Z., Borodi, P. G., Gergely, I., & Zuh, S.-G. (2021). Treatment Efficacy with a Novel Hyaluronic Acid-Based Hydrogel for Osteoarthritis of the Knee. Journal of Personalized Medicine, 11(4), 303. https://doi.org/10.3390/jpm11040303